- Home
- OTLK vs MRSN Comparison
OTLK vs MRSN Comparison
Compare OTLK & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLK
- MRSN
- Stock Information
- Founded
- OTLK 2010
- MRSN 2001
- Country
- OTLK United States
- MRSN United States
- Employees
- OTLK N/A
- MRSN N/A
- Industry
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- OTLK Health Care
- MRSN Health Care
- Exchange
- OTLK Nasdaq
- MRSN Nasdaq
- Market Cap
- OTLK 48.3M
- MRSN 40.7M
- IPO Year
- OTLK 2016
- MRSN 2017
- Fundamental
- Price
- OTLK $2.25
- MRSN $0.35
- Analyst Decision
- OTLK Strong Buy
- MRSN Strong Buy
- Analyst Count
- OTLK 5
- MRSN 5
- Target Price
- OTLK $9.60
- MRSN $5.75
- AVG Volume (30 Days)
- OTLK 987.3K
- MRSN 3.1M
- Earning Date
- OTLK 08-13-2025
- MRSN 08-12-2025
- Dividend Yield
- OTLK N/A
- MRSN N/A
- EPS Growth
- OTLK N/A
- MRSN N/A
- EPS
- OTLK 0.83
- MRSN N/A
- Revenue
- OTLK N/A
- MRSN $34,006,000.00
- Revenue This Year
- OTLK N/A
- MRSN N/A
- Revenue Next Year
- OTLK $419.06
- MRSN $1.03
- P/E Ratio
- OTLK $2.62
- MRSN N/A
- Revenue Growth
- OTLK N/A
- MRSN N/A
- 52 Week Low
- OTLK $0.87
- MRSN $0.26
- 52 Week High
- OTLK $9.10
- MRSN $2.83
- Technical
- Relative Strength Index (RSI)
- OTLK 67.03
- MRSN 52.71
- Support Level
- OTLK $2.16
- MRSN $0.32
- Resistance Level
- OTLK $2.45
- MRSN $0.38
- Average True Range (ATR)
- OTLK 0.16
- MRSN 0.03
- MACD
- OTLK 0.05
- MRSN 0.01
- Stochastic Oscillator
- OTLK 81.01
- MRSN 69.00
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.